Skip to main content

Articles

Page 1 of 40

  1. To conduct a real-word-study-based cost-effectiveness analysis of a GLP-1 receptor agonist (GLP-1RA) versus insulin among type 2 diabetes patients requiring intensified injection therapy and a systematic revie...

    Authors: Chen-Yi Yang, Ying-Ren Chen, Huang-Tz Ou and Shihchen Kuo

    Citation: Cardiovascular Diabetology 2021 20:21

    Content type: Original investigation

    Published on:

  2. The metabolic syndrome (MetS) and its components are associated with the development of atrial fibrillation (AF). However, the impact of time-burden of MetS on the risk of AF is unknown. We investigated the ef...

    Authors: Hyo-Jeong Ahn, Kyung-Do Han, Eue-Keun Choi, Jin-Hyung Jung, Soonil Kwon, So-Ryoung Lee, Seil Oh and Gregory Y. H. Lip

    Citation: Cardiovascular Diabetology 2021 20:20

    Content type: Original investigation

    Published on:

  3. The triglyceride–glucose (TyG) index, which is a simple surrogate marker of insulin resistance, has been suggested as a contributor of cardiovascular disease. However, evidence on the effect of long-term eleva...

    Authors: Xue Tian, Yingting Zuo, Shuohua Chen, Qian Liu, Boni Tao, Shouling Wu and Anxin Wang

    Citation: Cardiovascular Diabetology 2021 20:19

    Content type: Original investigation

    Published on:

  4. Mortality in individuals with diabetes with severe hypoglycemia requiring ambulance services intervention is high and it is unclear whether this is modifiable. Our aim was to characterise this high-risk group ...

    Authors: Sam M. Pearson, Beverley Whittam, Kavita Kulavarasalingam, Amelia Mitchell-Gears, Cathyrn James and Ramzi A. Ajjan

    Citation: Cardiovascular Diabetology 2021 20:18

    Content type: Original investigation

    Published on:

  5. Hospitalization for major diabetes complications, including myocardial infarction, stroke, lower-extremity amputation, and end-stage kidney disease, is on the rise and represents a great health burden for pati...

    Authors: Dario Giugliano, Miriam Longo, Lorenzo Scappaticcio, Paola Caruso and Katherine Esposito

    Citation: Cardiovascular Diabetology 2021 20:17

    Content type: Review

    Published on:

  6. Patients with diabetes and triple-vessel disease (TVD) are associated with a high risk of events. The choice of treatment strategies remains a subject of discussion. In the real-world, we aim to compare the ou...

    Authors: Xueyan Zhao, Lianjun Xu, Lin Jiang, Jian Tian, Yin Zhang, Dong Wang, Kai Sun, Bo Xu, Wei Zhao, Rutai Hui, Runlin Gao, Lei Song and Jinqing Yuan

    Citation: Cardiovascular Diabetology 2021 20:16

    Content type: Original investigation

    Published on:

  7. Previous studies have suggested that high mean glucose levels and glycemic abnormalities such as glucose fluctuation and hypoglycemia accelerate the progression of atherosclerosis in patients with type 2 diabe...

    Authors: Satomi Wakasugi, Tomoya Mita, Naoto Katakami, Yosuke Okada, Hidenori Yoshii, Takeshi Osonoi, Nobuichi Kuribayashi, Yoshinobu Taneda, Yuichi Kojima, Masahiko Gosho, Iichiro Shimomura and Hirotaka Watada

    Citation: Cardiovascular Diabetology 2021 20:15

    Content type: Original investigation

    Published on:

  8. Emerging evidence suggests that sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with decreased risk of cardiovascular and renal event...

    Authors: Takayuki Yamada, Mako Wakabayashi, Abhinav Bhalla, Nitin Chopra, Hirotaka Miyashita, Takahisa Mikami, Hiroki Ueyama, Tomohiro Fujisaki, Yusuke Saigusa, Takahiro Yamaji, Kengo Azushima, Shingo Urate, Toru Suzuki, Eriko Abe, Hiromichi Wakui and Kouichi Tamura

    Citation: Cardiovascular Diabetology 2021 20:14

    Content type: Original investigation

    Published on:

  9. Patients with diabetes and acute coronary syndrome (ACS) are at high risk for subsequent heart failure. Apabetalone is a selective inhibitor of bromodomain and extra-terminal (BET) proteins, epigenetic regulat...

    Authors: Stephen J. Nicholls, Gregory G. Schwartz, Kevin A. Buhr, Henry N. Ginsberg, Jan O. Johansson, Kamyar Kalantar-Zadeh, Ewelina Kulikowski, Peter P. Toth, Norman Wong, Michael Sweeney and Kausik K. Ray

    Citation: Cardiovascular Diabetology 2021 20:13

    Content type: Original investigation

    Published on:

  10. Diastolic dysfunction is highly prevalent in patients with type 2 diabetes mellitus (T2DM) and is associated with overweight, glucose dysregulation and coronary artery disease (CAD). The GLP-1 receptor agonist...

    Authors: Preman Kumarathurai, Ahmad Sajadieh, Christian Anholm, Ole P. Kristiansen, Steen B. Haugaard and Olav W. Nielsen

    Citation: Cardiovascular Diabetology 2021 20:12

    Content type: Original investigation

    Published on:

  11. Patients with type 2 diabetes mellitus (T2DM) are susceptible to coexisted with chronic kidney disease (CKD), which may increase cardiovascular mortality in these patients. The present study aimed to verify wh...

    Authors: Yi Zhang, Jin Wang, Yan Ren, Wei-feng Yan, Li Jiang, Yuan Li and Zhi-gang Yang

    Citation: Cardiovascular Diabetology 2021 20:11

    Content type: Original investigation

    Published on:

  12. We investigated the association of insulin resistance (IR) with coronary plaque morphology and the risk of cardiovascular events in patients enrolled in the Providing Regional Observations to Study Predictors ...

    Authors: Serdar Farhan, Björn Redfors, Akiko Maehara, Thomas McAndrew, Ori Ben-Yehuda, Bernard De Bruyne, Roxana Mehran, Birgit Vogel, Gennaro Giustino, Patrick W. Serruys, Gary S. Mintz and Gregg W. Stone

    Citation: Cardiovascular Diabetology 2021 20:10

    Content type: Original investigation

    Published on:

  14. Risk stratification of cardiovascular events in patients with type 2 diabetes mellitus (T2DM) has not been established. Coronary artery calcium score (CACS) and non-alcoholic fatty liver disease (NAFLD) are in...

    Authors: Keishi Ichikawa, Toru Miyoshi, Kazuhiro Osawa, Takashi Miki, Hironobu Toda, Kentaro Ejiri, Masatoki Yoshida, Yusuke Nanba, Masashi Yoshida, Kazufumi Nakamura, Hiroshi Morita and Hiroshi Ito

    Citation: Cardiovascular Diabetology 2021 20:8

    Content type: Original investigation

    Published on:

  15. Sodium–glucose linked transporter type 2 (SGLT-2) inhibition has been shown to reduce cardiovascular mortality in heart failure independently of glycemic control and prevents the onset of atrial arrhythmias, a...

    Authors: David Bode, Lukas Semmler, Paulina Wakula, Niklas Hegemann, Uwe Primessnig, Nicola Beindorff, David Powell, Raphael Dahmen, Hartmut Ruetten, Christian Oeing, Alessio Alogna, Daniel Messroghli, Burkert M. Pieske, Frank R. Heinzel and Felix Hohendanner

    Citation: Cardiovascular Diabetology 2021 20:7

    Content type: Original investigation

    Published on:

  16. In the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial) treatment with the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin significantly reduced heart failure hospitaliz...

    Authors: Matthias Rau, Kirsten Thiele, Niels-Ulrik Korbinian Hartmann, Alexander Schuh, Ertunc Altiok, Julia Möllmann, András P. Keszei, Michael Böhm, Nikolaus Marx and Michael Lehrke

    Citation: Cardiovascular Diabetology 2021 20:6

    Content type: Original investigation

    Published on:

  17. Evidence is limited about the joint health effects of the Mediterranean lifestyle on cardiometabolic health and mortality. The aim of this study was to evaluate the association of the Mediterranean lifestyle w...

    Authors: Mercedes Sotos-Prieto, Rosario Ortolá, Miguel Ruiz-Canela, Esther Garcia-Esquinas, David Martínez-Gómez, Esther Lopez-Garcia, Miguel Ángel Martínez-González and Fernando Rodriguez-Artalejo

    Citation: Cardiovascular Diabetology 2021 20:5

    Content type: Original investigation

    Published on:

  18. Tofogliflozin, an SGLT2 inhibitor, is associated with favorable metabolic effects, including improved glycemic control and serum lipid profile and decreased body weight, visceral adipose tissue, and blood pres...

    Authors: Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yosuke Okada, Keiichi Torimoto, Yutaka Umayahara, Hideaki Kaneto, Takeshi Osonoi, Tsunehiko Yamamoto, Nobuichi Kuribayashi, Kazuhisa Maeda, Hiroki Yokoyama, Keisuke Kosugi, Kentaro Ohtoshi…

    Citation: Cardiovascular Diabetology 2021 20:4

    Content type: Original investigation

    Published on:

  19. Individuals with diabetes and lower-limb complications are at high risk for cardiovascular and all-cause mortality, but uncertainties remain in terms of cancer-related death in this population. We investigated...

    Authors: Kamel Mohammedi, Stephen Harrap, Giuseppe Mancia, Michel Marre, Neil Poulter, John Chalmers and Mark Woodward

    Citation: Cardiovascular Diabetology 2021 20:3

    Content type: Original investigation

    Published on:

  20. The prevalence of cardiomyopathy is higher in diabetic patients than those without diabetes. Diabetic cardiomyopathy (DCM) is defined as a clinical condition of abnormal myocardial structure and performance in...

    Authors: Lin Wang, Yin Cai, Liguo Jian, Chi Wai Cheung, Liangqing Zhang and Zhengyuan Xia

    Citation: Cardiovascular Diabetology 2021 20:2

    Content type: Review

    Published on:

  21. Recent cardiovascular outcome trials have shown significant reductions in major cardiovascular (CV) events with glucagon-like peptide (GLP)-1 receptor agonists. Additionally, adjunctive surrogates for cardiova...

    Authors: Antonino Tuttolomondo, Anna Cirrincione, Alessandra Casuccio, Alessandro Del Cuore, Mario Daidone, Tiziana Di Chiara, Domenico Di Raimondo, Vittoriano Della Corte, Carlo Maida, Irene Simonetta, Stefania Scaglione and Antonio Pinto

    Citation: Cardiovascular Diabetology 2021 20:1

    Content type: Original investigation

    Published on:

  22. It has been suggested the COVID pandemic may have indirectly affected the treatment and outcome of STEMI patients, by avoidance or significant delays in contacting the emergency system. No data have been repor...

    Authors: Giuseppe De Luca, Miha Cercek, Lisette Okkels Jensen, Marija Vavlukis, Lucian Calmac, Tom Johnson, Gerard Roura i Ferrer, Vladimir Ganyukov, Wojtek Wojakowski, Clemens von Birgelen, Francesco Versaci, Jurrien Ten Berg, Mika Laine, Maurits Dirksen, Gianni Casella, Petr Kala…

    Citation: Cardiovascular Diabetology 2020 19:215

    Content type: Original investigation

    Published on:

  23. Type 2 diabetes (T2D) patients are at a greater risk of cardiovascular events due to aggravated atherosclerosis. Oxidized LDL (oxLDL) has been shown to be increased in T2D plaques and suggested to contribute t...

    Authors: Pratibha Singh, Isabel Goncalves, Christoffer Tengryd, Mihaela Nitulescu, Ana F. Persson, Fong To, Eva Bengtsson, Petr Volkov, Marju Orho-Melander, Jan Nilsson and Andreas Edsfeldt

    Citation: Cardiovascular Diabetology 2020 19:214

    Content type: Original investigation

    Published on:

  24. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Masatoki Yoshida, Kazufumi Nakamura, Toru Miyoshi, Masashi Yoshida, Megumi Kondo, Kaoru Akazawa, Tomonari Kimura, Hiroaki Ohtsuka, Yuko Ohno, Daiji Miura and Hiroshi Ito

    Citation: Cardiovascular Diabetology 2020 19:213

    Content type: Correction

    Published on:

    The original article was published in Cardiovascular Diabetology 2020 19:149

  25. Heart failure is a common and devastating complication of type 2 diabetes (T2D). Prompt recognition of heart failure may avert hospitalization, facilitate use of guideline-directed therapies, and impact choice...

    Authors: Suzanne V. Arnold, Philip G. Jones, Michael Beasley, Jeanine Cordova, Abhinav Goyal, Gregg C. Fonarow and Leo Seman

    Citation: Cardiovascular Diabetology 2020 19:212

    Content type: Original investigation

    Published on:

  26. The aim of this study was to investigate the association of visit-to-visit variability of hemoglobin A1c (HbA1c) and glycated albumin (GA) with the risk of lower extremity atherosclerotic disease (LEAD).

    Authors: Yun Shen, Dongjun Dai, Jingyi Lu, Yufei Wang, Wei Zhu, Yuqian Bao, Gang Hu and Jian Zhou

    Citation: Cardiovascular Diabetology 2020 19:211

    Content type: Original investigation

    Published on:

  27. Ischemic heart disease (IHD) without diabetes is considered an important challenge to human health and is associated with a poor prognosis, as well as a lack of health awareness. We prospectively investigated ...

    Authors: Byoungjin Park, Yong-Jae Lee, Hye Sun Lee and Dong-Hyuk Jung

    Citation: Cardiovascular Diabetology 2020 19:210

    Content type: Original investigation

    Published on:

  28. Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates cholesterol metabolism by targeting the low-density lipoprotein receptor. Recent studies have shown that circulating PCSK9 is associated with glu...

    Authors: Jie Shi, Weiwei Zhang, Yixin Niu, Ning Lin, Xiaoyong Li, Hongmei Zhang, Renming Hu, Guang Ning, Jiangao Fan, Li Qin, Qing Su and Zhen Yang

    Citation: Cardiovascular Diabetology 2020 19:209

    Content type: Original investigation

    Published on:

  29. We have previously reported that in patients with type 2 diabetes (T2D) consumption of a very low carbohydrate diet capable of inducing nutritional ketosis over 2 years (continuous care intervention, CCI) resu...

    Authors: Shaminie J. Athinarayanan, Sarah J. Hallberg, Amy L. McKenzie, Katharina Lechner, Sarah King, James P. McCarter, Jeff S. Volek, Stephen D. Phinney and Ronald M. Krauss

    Citation: Cardiovascular Diabetology 2020 19:208

    Content type: Original investigation

    Published on:

  30. Glucose oxidation is a major contributor to myocardial energy production and its contribution is orchestrated by insulin. While insulin can increase glucose oxidation indirectly by enhancing glucose uptake and...

    Authors: Qutuba G. Karwi, Cory S. Wagg, Tariq R. Altamimi, Golam M. Uddin, Kim L. Ho, Ahmed M. Darwesh, John M. Seubert and Gary D. Lopaschuk

    Citation: Cardiovascular Diabetology 2020 19:207

    Content type: Original investigation

    Published on:

  32. Information on the clinical characteristics and outcomes of hospitalized Covid-19 patients with or without diabetes mellitus (DM) is limited in the Arab region. This study aims to fill this gap.

    Authors: Abdullah M. Alguwaihes, Mohammed E. Al-Sofiani, Maram Megdad, Sakhar S. Albader, Mohammad H. Alsari, Ali Alelayan, Saad H. Alzahrani, Shaun Sabico, Nasser M. Al-Daghri and Anwar A. Jammah

    Citation: Cardiovascular Diabetology 2020 19:205

    Content type: Original investigation

    Published on:

  33. Diabetes is an increasingly important risk factor for ischemic stroke and worsens stroke prognosis. Yet a large proportion of stroke patients who are eventually diabetic are undiagnosed. Therefore, it is impor...

    Authors: Karl Matz, Jaakko Tuomilehto, Yvonne Teuschl, Alexandra Dachenhausen and Michael Brainin

    Citation: Cardiovascular Diabetology 2020 19:204

    Content type: Original investigation

    Published on:

  34. Early arterial healing after drug-eluting stent (DES) implantation may enable short dual-antiplatelet therapy (DAPT) strategy. The impact of diabetes mellitus (DM) on this healing has not been elucidated. We u...

    Authors: Takayuki Ishihara, Yohei Sotomi, Takuya Tsujimura, Osamu Iida, Tomoaki Kobayashi, Yuma Hamanaka, Takashi Omatsu, Yasushi Sakata, Yoshiharu Higuchi and Toshiaki Mano

    Citation: Cardiovascular Diabetology 2020 19:203

    Content type: Original investigation

    Published on:

  35. To evaluate the effects of cardiac resynchronization therapy (CRTd) in patients with type 2 diabetes mellitus (T2DM) optimized via automatic vs. echocardiography-guided approach.

    Authors: Celestino Sardu, Pasquale Paolisso, Valentino Ducceschi, Matteo Santamaria, Cosimo Sacra, Massimo Massetti, Antonio Ruocco and Raffaele Marfella

    Citation: Cardiovascular Diabetology 2020 19:202

    Content type: Original investigation

    Published on:

  36. Currently available treatments have only been partly successful in patients with severe hypertriglyceridemia, including those with high serum triglycerides above 1,000 mg/dL (11.3 mmol/L), who often suffer fro...

    Authors: Chie Iitake, Daisaku Masuda, Masahiro Koseki and Shizuya Yamashita

    Citation: Cardiovascular Diabetology 2020 19:201

    Content type: Original investigation

    Published on:

  37. Patients with type 2 diabetes (T2D) and metabolic syndrome (MetS) are at greater cardiovascular risk than those with T2D without MetS. In the current report we aim to study the characteristics, cardio-renal ou...

    Authors: João Pedro Ferreira, Subodh Verma, David Fitchett, Anne Pernille Ofstad, Sabine Lauer, Isabella Zwiener, Jyothis George, Christoph Wanner, Bernard Zinman and Silvio E. Inzucchi

    Citation: Cardiovascular Diabetology 2020 19:200

    Content type: Original investigation

    Published on:

  38. The Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) double blind randomized trial demonstrated that weekly subcutaneous dulaglutide 1.5 mg, a glucagon like peptide-1 receptor agon...

    Authors: Gilles R. Dagenais, Lars Rydén, Lawrence A. Leiter, Mark Lakshmanan, Leanne Dyal, Jeffrey L. Probstfield, Charles Messan Atisso, Jonathan E. Shaw, Ignacio Conget, William C. Cushman, Patricio Lopez-Jaramillo, Fernando Lanas, Ernesto German Cordona Munoz, Valdis Pirags, Nana Pogosova, Jan Basile…

    Citation: Cardiovascular Diabetology 2020 19:199

    Content type: Original investigation

    Published on:

  39. Metformin has been shown to have various cardiovascular benefits beyond its antihyperglycemic effects, including a reduction in stroke, heart failure, myocardial infarction, cardiovascular death, and all-cause...

    Authors: Teerapat Nantsupawat, Wanwarang Wongcharoen, Siriporn C. Chattipakorn and Nipon Chattipakorn

    Citation: Cardiovascular Diabetology 2020 19:198

    Content type: Review

    Published on:

  40. The relationship between adipocyte fatty acid-binding protein (AFABP) and cardiac remodelling has been reported in cross-sectional studies, although with conflicting results. Type 2 diabetes mellitus (T2DM) is...

    Authors: Mei-Zhen Wu, Chi-Ho Lee, Yan Chen, Shuk-Yin Yu, Yu-Juan Yu, Qing-Wen Ren, Ho-Yi Carol Fong, Pui-Fai Wong, Hung-Fat Tse, Siu-Ling Karen Lam and Kai-Hang Yiu

    Citation: Cardiovascular Diabetology 2020 19:197

    Content type: Original investigation

    Published on:

  41. Approximately half of all patients with type 2 diabetes (T2D) develop a certain degree of renal impairment. In many of them, chronic kidney disease (CKD) progresses over time, eventually leading to end-stage k...

    Authors: Francesco Giorgino, Jiten Vora, Peter Fenici and Anna Solini

    Citation: Cardiovascular Diabetology 2020 19:196

    Content type: Review

    Published on:

  42. We aimed to investigate the association of metabolic syndrome (MetS) and its single components with cardiovascular risk and estimated their impact on the prematurity of occurrence of cardiovascular events usin...

    Authors: María J. Guembe, Cesar I. Fernandez-Lazaro, Carmen Sayon-Orea, Estefanía Toledo and Conchi Moreno-Iribas

    Citation: Cardiovascular Diabetology 2020 19:195

    Content type: Original investigation

    Published on:

  43. The prevalence of peripheral artery disease (PAD) is obviously increased in patients with diabetes. Existing evidence shows that cysteine-rich angiogenic inducer 61 (Cyr61), a 40-kD secreted protein, plays imp...

    Authors: Bin Feng, Guidong Xu, Kangyun Sun, Kaipeng Duan, Bimin Shi and Nannan Zhang

    Citation: Cardiovascular Diabetology 2020 19:194

    Content type: Original investigation

    Published on:

  44. Type 2 Diabetes Mellitus (T2DM) is a well-known comorbidity to COVID-19 and coagulopathies are a common accompaniment to both T2DM and COVID-19. In addition, patients with COVID-19 are known to develop micro-c...

    Authors: Etheresia Pretorius, Chantelle Venter, Gert Jacobus Laubscher, Petrus Johannes Lourens, Janami Steenkamp and Douglas B. Kell

    Citation: Cardiovascular Diabetology 2020 19:193

    Content type: Original investigation

    Published on:

  45. Type 2 diabetes mellitus (T2DM) is associated with an increased cardiovascular risk related at least in part to a more vulnerable plaque phenotype. However, patients with T2DM exhibit also an increased risk fo...

    Authors: Rosalia Dettori, Andrea Milzi, Kathrin Burgmaier, Mohammad Almalla, Martin Hellmich, Nikolaus Marx, Sebastian Reith and Mathias Burgmaier

    Citation: Cardiovascular Diabetology 2020 19:192

    Content type: Original investigation

    Published on:

  46. The “obesity paradox” has not been elucidated in the long-term outcomes of acute coronary syndrome (ACS). We investigated the association between obesity and cardiovascular (CV) outcomes in ACS patients with a...

    Authors: Se-Jun Park, Kyoung Hwa Ha and Dae Jung Kim

    Citation: Cardiovascular Diabetology 2020 19:191

    Content type: Original investigation

    Published on:

  47. The well-established benefit of Low-Dense-Lipoprotein-cholesterol (LDL-c) lowering treatments (LLTs) has led clinical guidelines to lower the cardiovascular prevention targets. Despite this, there is a surpris...

    Authors: Mario Luca Morieri, Angelo Avogaro and Gian Paolo Fadini

    Citation: Cardiovascular Diabetology 2020 19:190

    Content type: Original investigation

    Published on:

  48. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) has shown evidence of cardiovascular benefit in patients with type 2 diabetes mellitus (T2DM). Currently metformin is the guideline-recommended first-line tr...

    Authors: Tien-Hsing Chen, Yan-Rong Li, Shao-Wei Chen, Yu-Sheng Lin, Chi-Chin Sun, Dong-Yi Chen, Chun-Tai Mao, Michael Wu, Chih-Hsiang Chang, Pao-Hsien Chu and Victor Chien-Chia Wu

    Citation: Cardiovascular Diabetology 2020 19:189

    Content type: Original investigation

    Published on:

  49. Sodium glucose cotransporter 2 inhibitor (SGLT2i) reduces the risk of hard cardiovascular endpoints in type 2 diabetes mellitus (T2DM) patients with/without established cardiovascular diseases. Whether SGLT2i ...

    Authors: Ann Wan-Chin Ling, Cze-Ci Chan, Shao-Wei Chen, Yi-Wei Kao, Chien-Ying Huang, Yi-Hsin Chan and Pao-Hsien Chu

    Citation: Cardiovascular Diabetology 2020 19:188

    Content type: Original investigation

    Published on:

  50. Depression and cardiovascular disease (CVD) are among the most common causes of disability in high-income countries, depression being associated with a 30% increased risk of future CV events. Depression is twi...

    Authors: C. Macchi, C. Favero, A. Ceresa, L. Vigna, D. M. Conti, A. C. Pesatori, G. Racagni, A. Corsini, N. Ferri, C. R. Sirtori, M. Buoli, V. Bollati and M. Ruscica

    Citation: Cardiovascular Diabetology 2020 19:187

    Content type: Original investigation

    Published on:

journal logo

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Submit manuscript

Annual Journal Metrics

Cardiovascular Diabetology

ISSN: 1475-2840